KHẢO SÁT MỐI TƯƠNG QUAN GIỮA THỊ LỰC VÀ SỰ THAY ĐỔI VI CẤU TRÚC VÙNG HOÀNG ĐIỂM TRÊN BỆNH NHÂN PHÙ HOÀNG ĐIỂM ĐÁI THÁO ĐƯỜNG BẰNG MÁY OCT

Abstract

Background: The purpose of this study was to evaluate the short-term response of intravitreal
bevacizumab in diabetic macular edema (DME) and assess the variation in treatment outcomes in different morphology patterns using spectral domain–optical coherence tomography (SD-OCT). Design: Observational, Prospective, Longitudinal Study. Participants: 33 eyes of 33 patients with diabetic macular edema were included. Methods: Thirty three eyes of 33 patients with DME were included and treated with intravitreal bevacizumab (1.25 mg/0.05 ml monthly for 3 months). The morphological patterns of DME were classified on the basis of OCT into three groups – diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD) – and changes in central macular thickness (CMT) and best corrected visual acuity (BCVA) after treatment were compared. Results: A total of 33 eyes with DME were included and consisted of 14 DRT, 10 CME, and 9 SRD. Treatment with bevacizumab resulted in decrease in central macular thickness and improvement in BCVA in all three groups. The baseline visual acuity and CMT of DRT group was better than that of the other two groups. The treatment outcome was measured in terms of CMT and BCVA. Change in CMT was statistically significant among three groups and was found to be better in DRT group (p<0.05). There was statistically significant variation between the three groups regarding the change in BCVA (p<0,05). Conclusions: DRT, which appears to be the earliest form of DME, responds better than other types. Thus, the pattern of macular edema shown by OCT may provide an objective guideline in predicting the response of bevacizumab injection in DME